Drug profile · INN
busulfan
MYLERAN
busulfan (MYLERAN) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Drug details — busulfan
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 21
- Data quality
- 0.89
Quick answer
busulfan (MYLERAN) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12318427
Methods and compositions for modulation of tau proteins
granted -
US 12139517
Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof
granted -
US 12043650
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11981967
Engineering AAV
granted -
US 11859190
Methods and compositions for regulation of transgene expression
granted -
US 11845965
Regulation of gene expression using engineered nucleases
granted -
US 11827900
Engineered target specific nucleases
granted -
US 11793888
Methods and compositions for engineering immunity
granted -
US 11723952
Methods and compositions for treating Huntington's Disease
granted -
US 11690921
Delivery of target specific nucleases
granted -
US 11661611
Genetic modification of cytokine inducible SH2-containing protein (CISH) gene
granted -
US 11661612
DNA-binding proteins and uses thereof
granted -
US 11655275
Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene
granted -
US 11648267
Methods and compositions for gene inactivation
granted -
US 11639504
Methods and compositions for regulation of transgene expression
granted -
US 11634463
Methods and compositions for treating hemophilia
granted -
US 11504389
Tau modulators and methods and compositions for delivery thereof
granted -
US 11452782
Liver-specific constructs factor VIII expression cassettes and methods of use thereof
granted -
US 11401512
Engineered target specific nucleases
granted -
US 11235026
Methods and compositions for modulating PD1
granted
Frequently asked questions
What is busulfan?
busulfan (MYLERAN) is a dna inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for busulfan?
MYLERAN is a marketed brand name for busulfan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of busulfan?
busulfan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.